Event Calendar

Jun 23, 2022 at 10:00 AM EDT

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webinar on the cost of managing surgical site infections (“SSIs”) on Thursday, June 23, 2022, at 10:00 AM Eastern Time.

The webinar will feature presentations from KOLs Kyle Cologne, M.D., Los Angeles County General – USC Medical Center, who will provide a general-hospital perspective on the cost of managing SSIs, and Elliot Goodman, M.D., Mount Sinai Health System, who will discuss the impact SSIs have on quality measures and performance from an integrated delivery network (IDN) perspective.

The PolyPid leadership team will provide a corporate update, including a discussion on the timing of the topline results following the recent completion of patient enrollment in the SHIELD I Phase 3 study of D-PLEX100 for the prevention of SSIs in abdominal surgery.

A question and answer session will follow. To register for the event, please click here.

Jun 15, 2022 at 11:00 AM EDT

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is being held in New York City, on June 15-16, 2022.

 

JMP Securities 2022 Life Sciences Conference:
Presentation Date:  Wednesday, June 15, 2022
Presentation Time: 11:00 AM Eastern Time

 

Investors interested in meeting with PolyPid during the conference should contact their JMP representative.

May 11, 2022 at 8:30 AM EDT

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:  Wednesday, May 11, 2022
Time: 8:30 AM Eastern Time
United States: +1 877-870-9135
Israel: +972 1809 213-985
International: +44 (0) 2071 928338
Conference ID: 3450787

May 2 - May 4, 2022

PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year’s summit is From Hope to Product The Brilliant Prospect in Nanomedicine and Related Fields.

Dr. Noam Emanuel, Chief Scientific Officer of PolyPid, will present the abstract, ‘From Bench to Bedside: D-PLEX100 Limits AMR Occurrence in Randomized Double-Blind Phase 2 Trial in Colorectal Surgery Patients,’ demonstrating D-PLEX100 as a safe and effective surgical site infection prevention agent without affecting the incidence of postoperative colonization by multi drug resistant organisms. Dr. Emanuel’s presentation will be available on https://www.polypid.com/ following the summit.

Apr 23 - Apr 26, 2022

PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dallas, TX.

The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation, evaluates the addition of D-PLEX100 to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the presentation.

Mar 15 - Mar 17, 2022

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.

 

Barclays Global Investor Conference:

Presentation Date:  Wednesday, March 16, 2022
Presentation Time: 9:00 AM Eastern Time
   

Feb 9, 2022 at 8:30 AM EST

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Nov 10, 2021 at 8:30 AM EST

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, November 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >